Hanoi, November 5th, 2023 – Bayer Vietnam and the Vietnam National Heart Association have established a strategic partnership to address the challenges and improve the management of cardiovascular diseases in Vietnam. The collaboration aims to enhance medical knowledge, clinical skills, and patient care outcomes, particularly in relation to thrombosis-related diseases such as atrial fibrillation, venous thromboembolism, coronary artery disease, and peripheral artery disease.
Bayer and the Vietnam National Heart Association join forces to improve quality of cardiovascular disease management.
Bayer Vietnam and the Vietnam National Heart collaborated in the program "Improving the Quality of Training and Management of Cardiovascular Disease for Doctors and the Community, 2024-2025".
According to WHO, cardiovascular diseases were responsible for 31% of total deaths. Lifestyle changes, such as sedentary habits, unhealthy diets, tobacco use, increased stress levels, and aging population is associated with an increased incidence of cardiometabolic disease, including thrombosis related condition. The rising demand for healthcare services and specialized interventions creates pressure on the healthcare system, not to mention the financial burden associated with diagnosing, treating, and managing cardiovascular diseases on patients and their families. In light of these challenges, it is required to have effective strategies for prevention, early detection, and timely management.
Under the program "Improving the Quality of Training and Management of Cardiovascular Disease for Doctors and the Community, 2024-2025," Bayer Vietnam and Vietnam National Heart Association will join forces to tackle this issue head-on. Scientific conferences and continuous medical education programs will be organized to update medical knowledge and enhance the skills of healthcare professionals, with a specific focus on provincial capacity building. Regular updates to treatment recommendations for thrombosis-related diseases will ensure that healthcare providers have the latest information on most advanced and effective approaches at their disposal.
In addition to its commitment to disease management and comprehensive healthcare, Bayer Vietnam's radiology division will support to improve healthcare professionals' understanding and skills in utilizing advanced imaging technologies for the precise diagnosis of cardiovascular conditions. This will enable them to develop personalized treatment plans, monitor disease progression, and provide targeted care to patients, improving overall healthcare outcomes.
Prof. Dr. Huynh Van Minh of Vietnam National Heart Association had a speech at the event
Prof. Dr. Huynh Van Minh of Vietnam National Heart Association: "Our collaboration with Bayer Vietnam marks an important milestone in our efforts to enhance cardiovascular disease management in Vietnam. By combining our expertise and resources, we can develop innovative solutions, conduct impactful research, and deliver comprehensive training programs. Together, we will empower medical professionals, raise awareness in the community, and improve patient outcomes. We are excited about the positive impact this partnership will have on cardiovascular care and the health and well-being of the Vietnamese population."
Furthermore, empowering patients with knowledge about cardiovascular diseases is crucial for early detection, adherence to treatment plans, and lifestyle modifications. This partnership will also work to develop educational materials to raise public awareness about risk factors, symptoms, and prevention strategies of thrombotic diseases, empowering individuals to take an active role in their healthcare journey. And by promoting a culture of proactive healthcare-seeking behaviours and patient engagement, the overall management of these diseases can be significantly improved.
Ingo Brandenburg, Managing Director of Bayer Vietnam shared that Bayer's efforts aim to improve the understanding of cardiovascular diseases and find innovative approaches for patients
Ingo Brandenburg, Managing Director of Bayer Vietnam shared: “At Bayer, we are proud of our heritage in providing new treatment options for patients suffering from heart and blood conditions. Aiming at reducing the burden that cardiovascular diseases pose to families, community and society, Bayer is working in collaboration with leading scientific, academic and industry partners to improve our understanding of cardiovascular diseases and find innovative approaches for patients. We encourage active involvement of patients and their families in prevention efforts and treatment compliance via wide range of health awareness initiatives for communities on multiple platforms, as their participation is a core factor for effective disease management and control.”
The collaboration between Bayer Vietnam and the Vietnam National Heart Association comes at a right time when concerted efforts are needed. By combining expertise, resources, and a shared vision, this partnership aims to address the challenges faced by healthcare professionals, patients, and the healthcare system. Through research, education, and the development of comprehensive programs, the collaboration endeavours to improve the prevention, diagnosis, and management of cardiovascular diseases and ultimately enhance the health and well-being of the Vietnamese population.
Additional information box:
Bayer Vietnam is proud to be the one of the sponsors for the 27th Congress of the ASEAN Federation of Cardiology, hosted by the Vietnam National Heart Association from November 2nd to 5th, 2023 in Hanoi. With the theme "Cardiology at the Crossroads: Challenges and Opportunities," this prestigious scientific program focuses on managing cardiovascular diseases amidst multiple comorbidities, utilizing advanced interventions, technology, artificial intelligence, and telemedicine. The congress aims to explore innovative approaches while considering limited resources in the ASEAN region and fostering collaboration with developed foreign partners and countries.
During the event, the Vietnam National Heart Association and Bayer Vietnam officially announce their strategic partnership through the signing of a memorandum of understanding (MoU), strengthening collaborations to advance cardiovascular care and improve patient outcomes.
About Vietnam National Heart Association
Vietnam National Heart Association is a non-profit professional organization which desires to promote the cardiovascular health, welfare and wellbeing of the population in Vietnam. The objective of VNHA is to share information, knowledge and experience among the cardiologists in Vietnam.
About Bayer
Bayer is a global enterprise with core competencies in the life science fields of healthcare and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability, and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.